FGFR2 and liposarcoma: In FGFR2-overexpressing myxoid liposarcoma cell lines, the FGFR TKIs PD173074, dovitinib and infigratinib, reduced cell proliferation and migration, and this effect was further increased by their combination with the standard chemotherapeutic agent trabectedin [41].